Aalto Bio Reagents, Dublin, Ireland, has launched an RNA lysis buffer reagent for the pretreatment of covid-19 samples prior to testing.

No-one

Philip Noone, Aalto Bio Reagents.

The RNA lysis buffer reagent was developed in response to the unavailability of a similar reagent from other manufacturers in Europe. The volume of polymerase chain reaction tests being carried out for covid-19 in Ireland—and around the world—is such that manufacturers simply cannot produce the volume of reagents required.

“Aalto Bio Reagents were happy to step up and develop a reagent from scratch to alleviate some of the pressure around covid-19 testing,” says Philip Noone, chief executive officer of Aalto Bio Reagents. “We will continue to offer assistance to address any bottlenecks that may exist in the covid-19 diagnostic testing supply chain.”

For more information, visit Aalto Bio Reagents.